Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.

Publication Type:

Journal Article


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 26, Issue 2, p.211-7 (2008)


2008, Adult, Aged, Center-Authored Paper, Clinical Research Division, DISEASE PROGRESSION, Disease-Free Survival, Female, Flow Cytometry Core Facility, hematopoietic stem cell transplantation, Humans, Lymphoma, Non-Hodgkin, Male, Middle Aged, RECURRENCE, Research Trials Office Core Facility - Biostatistics Service, Shared Resources, Survival Rate, Transplantation Conditioning, Transplantation, Homologous, Treatment Outcome


Few effective treatment options exist for chemotherapy-refractory indolent or transformed non-Hodgkin's lymphoma (NHL). We examined the outcome of nonmyeloablative allogeneic hematopoietic cell transplantation (HCT) in this setting.